BridgeBio Unveils ATTR-CM Awareness Campaign as Phase 3 Data Shows 50% Hospitalization Cut
BridgeBio launched a 'Don’t Pass On Your Heart Health' campaign with Morgan Freeman and Howard White to raise awareness of underdiagnosed ATTR-CM in those over 55, noting 1 in 25 Black individuals carry the V142I variant. Phase 3 ATTRibute-CM data showed Attruby reduces cardiovascular hospitalizations by 50% at 30 months.
1. Campaign Launch and Objectives
BridgeBio launched the 'Don’t Pass On Your Heart Health' campaign with Morgan Freeman and Howard White to raise awareness of underdiagnosed ATTR-CM in those over 55, emphasizing the importance of early symptom recognition and diagnosis.
2. Disease Awareness and Demographics
ATTR-CM occurs when misfolded TTR protein builds up in the heart, often misdiagnosed as common heart failure or aging, with 1 in 25 Black individuals carrying the V142I variant and facing higher risk and diagnostic delays.
3. Phase 3 ATTRibute-CM Study Outcomes
The Phase 3 ATTRibute-CM trial showed that Attruby stabilized TTR protein within four weeks, reduced cardiovascular-related hospitalizations by 50% at 30 months, and improved patient quality of life with mostly mild, transient side effects.
4. Market Implications
Increased awareness and early diagnosis efforts could expand the addressable patient pool and drive Attruby adoption, potentially boosting revenue growth and supporting BridgeBio’s valuation as clinical benefits become more widely recognized.